• 1 January 1977
    • journal article
    • research article
    • Vol. 73  (2) , 293-296
    • PMID:834068
Abstract
Successful treatment of fungal [Candida] endocarditis is being described with increasing frequency. Two patients, previously reported as free of disease by 2 different groups of investigators, subsequently died with evidence of continued disease. Both patients received antifungal chemotherapy [amphotericin B, 5-fluorocytosine] at the time their case histories were reported. The lack of clinical signs and symptoms in fungal endocarditis, the suppression of manifestations of infection by chemotherapy and the uncertain reliability of laboratory aids led to guidelines in reporting results of therapeutic regimens. These include avoidance of terms implying cure in patients who are concurrently maintained on chemotherapy, indication of attempts to evaluate fungemia and minimum follow-up of 1-2 yr duration. The potential utility of serologic studies is illustrated by the course of 1 of these patients.